The Effect of Nociception Level (NOL) Monitoring on Intraoperative Opioid Consumption in Hip Surgeries
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mehmet Bulut
- Phone Number: +902623038248
- Email: bulutmehmet114@gmail.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ASA (American Society of Anesthesiologists) physical status classification I-IV patients who are planned to undergo hip surgery
Exclusion Criteria:
- Allergies to study medications
- serious renal, pulmonary, liver and endocrine diseases
- have a history of chronic pain
- Those with a history of bleeding diathesis
- Those with increased intracranial pressure
- Those with severe mitral and/or aortic stenosis
- patients with psychiatric diseases and communication difficulties
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Analgesic use according to hemodynamics patients to be treated
Procedure/Surgery: Pericapsular nerve group block(PENG) Before the general anesthesia induction, Peng block will be performed between the psoas tendon and the ilium with 0.25% bupivacaine (20 mL) using ultrasound and will be adjusting opioid infusion rate according to hemodinamic parameters
|
Patient who will be adjusted according to hemodynamic parameter
|
|
Active Comparator: Patients who will use analgesics according to NOL monitoring
Procedure/Surgery: Pericapsular nerve group block(PENG) Before the general anesthesia induction, Peng block will be performed between the psoas tendon and the ilium with 0.25% bupivacaine (20 mL) using ultrasound and will be adjusting opioid infusion rate according to NOL monitoring.
|
Patient who will be adjusted according to NOL monitoring
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Remifentanil consumption
Time Frame: Intraoperative
|
Total amount of remifentanil used during the surgery (mg)
|
Intraoperative
|
|
NRS Scores
Time Frame: Postoperative 1st, 6th, 12th and 24th hours
|
Numeric Rating Scale scores, between 0-10 (0= no pain, 10=worst pain imaginable)
|
Postoperative 1st, 6th, 12th and 24th hours
|
|
Morphine consumption
Time Frame: Postoperative 1st, 6th, 12th and 24th hours
|
Amount of morphine in the postoperative period (mg)
|
Postoperative 1st, 6th, 12th and 24th hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rescue analgesic
Time Frame: Postoperative 1st, 6th, 12th and 24th hours
|
The use of rescue analgesic
|
Postoperative 1st, 6th, 12th and 24th hours
|
|
Nausea and vomiting
Time Frame: Postoperative 1st, 6th, 12th and 24th hours
|
If the patient had nausea or vomiting, it will be recorded.
|
Postoperative 1st, 6th, 12th and 24th hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Hadi Ufuk Yörükoğlu, Kocaeli University, Department of Anesthesiology and Reanimation
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KAD-DD- 01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Use
-
NCT04927143RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine Abuse
-
NCT04556552CompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance Withdrawal
-
NCT04394559Active, not recruitingOpioid Dependence | Opioid Use | Opioid-use Disorder
-
NCT05995873RecruitingOpioid Dependence | Opioid Use | Opioid Abuse | Opiate Dependence | Opioid Use, Unspecified | Opioid Use Disorder, Moderate
-
NCT05103787Recruiting
-
NCT04396587Completed
Clinical Trials on Those whose opioids were adjusted according to hemodynamic parameters
-
NCT05476952CompletedBody Weight Changes | Intubation Conditions | Rocuronium